1. Home
  2. DTSS vs BLRX Comparison

DTSS vs BLRX Comparison

Compare DTSS & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Datasea Inc.

DTSS

Datasea Inc.

HOLD

Current Price

$0.96

Market Cap

9.0M

Sector

Technology

ML Signal

HOLD

Logo BioLineRx Ltd.

BLRX

BioLineRx Ltd.

HOLD

Current Price

$2.33

Market Cap

12.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DTSS
BLRX
Founded
2014
2003
Country
China
Israel
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.0M
12.6M
IPO Year
2015
2010

Fundamental Metrics

Financial Performance
Metric
DTSS
BLRX
Price
$0.96
$2.33
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$19.00
AVG Volume (30 Days)
26.6K
13.2K
Earning Date
05-13-2026
03-23-2026
Dividend Yield
N/A
N/A
EPS Growth
82.42
N/A
EPS
N/A
N/A
Revenue
$71,616,820.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
198.70
N/A
52 Week Low
$0.64
$2.28
52 Week High
$2.70
$7.77

Technical Indicators

Market Signals
Indicator
DTSS
BLRX
Relative Strength Index (RSI) 51.20 44.88
Support Level $0.81 N/A
Resistance Level $0.98 $2.76
Average True Range (ATR) 0.11 0.18
MACD 0.01 -0.02
Stochastic Oscillator 60.32 52.06

Price Performance

Historical Comparison
DTSS
BLRX

About DTSS Datasea Inc.

Datasea Inc is a technology company that operates in two main segments. The first segment, Acoustic High-Tech, focuses on developing and applying acoustic technologies, such as ultrasound, infrasound, and mechanical wave effects, for applications like ultrasonic sterilization, neuro-regulation, acupoint stimulation, and environmental purification. The second segment, AI Multimodal Digitalization, integrates artificial intelligence with 5G networks and big data processing to create a proprietary multimodal data platform that combines text, voice, image, and video for real-time intelligent analysis and generation. The company generates all of its revenue from the People's Republic of China (PRC).

About BLRX BioLineRx Ltd.

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Share on Social Networks: